More than 30 million people in the U.S. and 350 million globally are impacted by one of 7,000 distinct rare diseases, and the National Institutes of Health estimates that half of all people affected by rare diseases are children.1
You are here
Applying Rare Disease Research to Uncover New Therapies
Pfizer is uniquely positioned to lead advances in rare disease treatment.
Investigating the Next Wave of Innovation to Help People with Hemophilia
Over the past 25 years, genes responsible for approximately 50% of the monogenic diseases2, diseases where a single gene is mutated, have been identified and it is estimated that the remaining disease-causing genes will be known by the year 2020.3
Scientific advances over the past decade have increased understanding of rare diseases and their underlying causes, even enabling the development of critical treatment options for some. But today, just 5% of rare diseases have an available therapeutic, and a significant unmet medical need remains.4
At Pfizer, we are making important strides in our,
understanding of rare diseases.
understanding of rare diseases.
At Pfizer, we are making important strides in our understanding of rare diseases and there is tremendous opportunity for patients driven by recent scientific breakthroughs to enable the discovery and development of new medicines.
A majority of rare diseases are caused by a single gene mutation, and thanks to genome sequencing, we now have clues that lead us in the best direction for potential therapies. This is key for Pfizer as we focus on monogenetic diseases, partly through our gene therapy efforts.
With more than 20 years of experience in rare disease research, treatments approved in 81 countries, and multiple drugs in clinical trials, Pfizer is uniquely positioned to lead advances in rare disease treatment. We are focused on two main areas of research in rare disease:
Hematologic DiseasesAn area where Pfizer has a long heritage in Hemophilia and where we’re excited about our collaboration with Spark Therapeutics, Inc. The next frontier for us is in Sickle Cell Disease, a devastating condition with a high unmet need for new treatments. We have assets in our pipeline that have that may manage the disease, and others that may actually modify the course of the disease.
Neuromuscular Diseases These often inherited diseases can be debilitating and cause muscle weakness, and in some cases, can even impact heart function and one’s ability to breathe. We are focusing our efforts in Duchenne Muscular Dystrophy, and other neuromuscular diseases. Through our acquisition of Bamboo Therapeutics Inc., we have preclinical programs in Friedreich’s Ataxia and Canavan disease, and a Phase I asset for Giant Axonal Neuropathy.
Gene therapy is a promising investigational technology, especially for patients with rare diseases.
Gene therapy is an emerging area of medical research focused on developing highly specialized, one-time, transformative treatments aimed at addressing the root cause of diseases caused by genetic mutation. Gene therapy is a promising investigational technology, especially for patients with rare diseases, many of which are caused by a single genetic mutation.
The technology involves introducing genetic material into the body to deliver a corrected copy of a gene to a patient’s cells to compensate for a defective one. The genetic material can be delivered to the cells by a variety of means, one of which is uses a viral vector such as recombinant Adeno-Associated Virus (rAAV).
The technology involves introducing genetic material into the body to deliver a corrected copy of a gene to a patient's cells…
To bolster our capabilities in gene therapy, Pfizer acquired Bamboo Therapeutics, Inc., a privately held biotechnology company based in Chapel Hill, N.C., focused on developing gene therapies for the potential treatment of patients with certain rare diseases related to neuromuscular conditions and those affecting the central nervous system. This acquisition significantly expands Pfizer’s expertise in gene therapy by providing Pfizer with clinical and several preclinical assets that complement the company’s rare disease portfolio, an advanced rAAV vector design and production technology, and a fully functional Phase 1/2 gene therapy GMP manufacturing facility that Bamboo acquired from the University of North Carolina.
Our strategy is focused on accessing the most effective vector design and manufacturing scalability to ensure we are phase 1/2 ready. We are building capabilities in gene therapy while also collaborating with some of the leading experts in this field:
Our collaboration with Spark Therapeutics, Inc. where we are jointly investigating SPK-9001 and its potential in hemophilia B. SPK-9001 received breakthrough therapy designation from the U.S. Food and Drug Administration to help expedite the development and FDA review of the investigational candidate.
Collaboration is key to success in rare diseases. At Pfizer, we pride ourselves in stretching the limits of traditional models of collaboration, working with innovators in government, academia, patient advocacy organizations and across the industry in new and important ways. The power of a networked R&D model that leverages the strengths of all sectors will drive the next generation of breakthrough therapies.
Pfizer is in constant engagement with patients to fully understand their needs…
From the earliest discovery phase, Pfizer is engaging to fully understand the needs of patients and to gain insights to help both patients and caregivers. In our engagement with advocacy and patient communities we hope to advance science together with ideas that could ultimately result in better therapies. Patient foundations play a pivotal role in rare disease R&D, helping amplify and accelerate efforts to bring potential therapies to areas where there are very limited, if any, treatment options. At Pfizer, our patient foundation partners work with our R&D teams to help de-risk early stages of research, prioritize endpoints, support clinical trial recruitment, and provide insight into disease.
Work with Us
If you’re interested in collaborating with our Rare Disease research team and want to learn more about work, visit our Rare Diseases Partnering page. We welcome the opportunity to discuss how we can work together.